target directory

autologous fecal matter transplant clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT06609980
Source recordAI-normalized

Fecal Microbiota Transplantation (Autologous) in Infants Treated With Antibiotics

Antibiotics are lifesaving therapeutic drugs which have been used by adults, children, and infants alike for decades. There is an increase in global use of antibiotics over the course of lifetime and earlier in lifetime, with some countries recording as high as 12 courses a year in children younger than two. While antibiotics are successful in eradicating many pathogenic bacteria, research has demonstrated significant effect on beneficial gut microbiota, including long-lasting shift in the dynamics, composition, richness, and maturity of the intestinal flora. Microbiota alterations during early life, including through antibiotics use as well as birth via C-section, constitute a developmental perturbation, which increases the risk of modern diseases of immune and metabolic dysfunction. Strong epidemiological evidence suggests associations between early stressors of the microbiota and a number of common diseases, such as obesity, asthma, allergies, celiac disease, and Type 1 Diabetes. Furthermore, excess antibiotic exposure is associated with the development of neurological and psychiatric disorders. Currently, no strategies exist to restore the microbiome other than reliance on spontaneous repair mechanism, which often takes months in a healthy individual barring further antibiotic exposure. Contrary to popular belief, ingestion of probiotics, particularly after antibiotics, has been demonstrated to slow down the repair as it introduces an exogenous and massive amounts of only a few types of bacterial strains into a finely-tuned ecosystem of hundreds of different strains. It is hypothesized that by preserving the child's microbiome prior to antibiotic therapy and reintroducing it afterwards through an autologous fecal matter transplant (FMT) will assist in a quick, effective, and host-specific microbiome recolonization to the levels and patterns to those prior to antibiotics. This would in turn reduce the overall loss of microbiome diversity over the child's lifespan, essentially providing a 'reset' option to the child's most unadulterated version of microbiome. This approach utilizes delivering the sample by mixing it in maternal milk or formula and feeding it to the child through a bottle, which can be performed anywhere without any discomfort for the child.

AI analysis

Indication: Antibiotic Treatment

Modality: microbiome therapy

Target: autologous fecal matter transplant

Sponsor: Rutgers, The State University of New Jersey

Source URL: ClinicalTrials.gov

Source updated: May 13, 2026

Ingested: Jun 07, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: autologous fecal matter transplant

View original source fields

Condition raw: Antibiotic Treatment

Condition normalized: Antibiotic Treatment

Modality raw: microbiome therapy

Modality normalized: microbiome therapy

Target raw: autologous fecal matter transplant

Target normalized: autologous fecal matter transplant

Open report